

CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#)



Cite this: *Biomater. Sci.*, 2024, **12**, 6149

DOI: 10.1039/d4bm90077d
rsc.li/biomaterials-science

Correction: The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer

Wancun Zhang,^a Lili Xia,^b Xiangyu Ren,^b Mengyuan Cui,^b Tianguang Liu,^b Chen Ling,^b Yanqi Xu,^b Dawei Deng,^b Xianwei Zhang,^a Yueqing Gu^b and Peng Wang^{*a,b}

Correction for 'The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer' by Wancun Zhang *et al.*, *Biomater. Sci.*, 2020, **8**, 5941–5954, <https://doi.org/10.1039/D0BM01035A>.

The authors regret that an incorrect version of Fig. 3 was included in the original article. The correct version of Fig. 3 is presented below. The authors note that the correction does not change the conclusions of the paper.

1. In Fig. 3B, the control group images were reused due to an oversight by the authors. The crystal violet staining images for the PBS, aspirin, and BSA@DA groups at 24 hours have now been corrected according to Fig. S7 in the ESI, and Fig. S7 in the ESI has been updated accordingly. These corrections do not affect the validity of our experimental conclusions (page 5947).

2. In Fig. 3D, the cell scratch images for 0 hours and 36 hours in the FA-BSA@DA group were inadvertently reused. To prevent any potential misinterpretation, we have corrected these images as shown herein. These corrections do not affect the validity of our experimental conclusions (page 5947).




Fig. S7 The images of cell migration after treatment with PBS, aspirin, BSA@DA, and different concentrations of FA-BSA@DA at 12 h and 24 h.

^aHenan Key Laboratory of Children's Genetics and Metabolic Diseases, Henan Neurodevelopment Engineering Research Center for Children, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450018, China. E-mail: wangpeng159seu@hotmail.com

^bDepartment of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198, China






Fig. 3 The *in vitro* therapeutic effects of FA-BSA@DA. (A) Transwell assays were performed to establish a metastasis model. (B) The inhibitory effects of FA-BSA@DA on the migration of metastatic 4T1 cancer cells. (C) The quantification of the antimigration effects on metastatic 4T1 cancer cells, $*p < 0.05$, $**p < 0.005$, $***p < 0.0005$. (D) The scratch test also confirmed that migration was inhibited in 4T1 breast cancer cells. (E) The quantification of the scratch test results. (F) The expression of heparanase in 4T1 cancer cells after treatment with PBS, aspirin, BSA@DA, and FA-BSA@DA. (G) The relative grayscale value of heparinase, $***p < 0.0005$.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.